Morris, Stephen
Vallortigara, Julie
Greenfield, Julie
Hunt, Barry
Hoffman, Deborah
Reinhard, Carola
Graessner, Holm
Federico, Antonio
Quoidbach, Vinciane
Giunti, Paola http://orcid.org/0000-0003-3508-4788
Funding for this research was provided by:
Medical Research Council (MR/N028767/1)
Takeda Pharmaceuticals U.S.A. (Takeda Pharmaceuticals U.S.A.)
Reata Pharmaceuticals (Reata Pharmaceuticals)
European Brain Council (European Brain Council)
Article History
Received: 11 October 2023
Accepted: 18 November 2023
First Online: 7 December 2023
Declarations
:
: In the UK the survey was submitted for ethical approval via the Integrated Research Application System (IRAS; reference 252966) and received approval by the Cambridge Research Ethics Committee (REC; reference 19/EE/0030). As part of this process all materials related to the survey, including the patient information sheets and final questionnaire, were validated by a clinical expert and an informal review panel including ataxia patients, nominated by Ataxia UK. For the two other countries, ethical approval for an anonymised survey was not needed.
: Not applicable.
: None of the authors declare any competing interests.